CR Pharma, CR Medical extend supply chain deal to 2028

China Resources Pharmaceutical Group Limited (CR Pharmaceutical) and China Resources Medical Holdings Company Limited (CR Medical) have entered into a new Cooperation Framework Agreement 2026/2028. This agreement is effective from January 1, 2026, to December 31, 2028. Under this agreement, CR Medical Group will continue to provide Supply Chain Management Services for medical supplies to CR Pharmaceutical Group, aiming to enhance efficiency and reduce costs.

The new agreement replaces the existing framework, which expires on December 31, 2025. CR Medical Group will receive management service fees from CR Pharmaceutical Group for these services. The proposed annual caps for these transactions are set at RMB170,000,000 for each year ending December 31, 2026, 2027, and 2028.

As of the announcement date, China Resources (Holdings) Company Limited (CRH) holds 53.40% equity interest in CR Pharmaceutical and 36.58% in CR Medical. This makes them connected persons, and the transactions constitute continuing connected transactions under Chapter 14A of the Listing Rules, subject to reporting, announcement, and annual review requirements.